Improvement of contractility accompanies angiogenesis rather than arteriogenesis in chronic myocardial ischemia

Vascular Pharmacology
Claudia HeilmannHeike Göbel

Abstract

Growth factor therapy provides a therapeutic alternative for "no option" patients with coronary disease. Fibroblast Growth Factor-2 (FGF-2) predominantly stimulates angiogenesis, the growth of new capillaries, whereas Monocyte Chemoattractant Protein-1 (MCP-1) is considered an arteriogenic agent. We hypothesised a synergetic effect of FGF-2 and MCP-1 in ischemic myocardium. A severe coronary stenosis was created in pigs. After one week, chronic ischemia was confirmed by angiography, echocardiography, reduced ejection fraction, and increase of marker enzymes. FGF-2, MCP-1, both, or vector only were then injected intramyocardially as plasmid DNA in the impaired area. Regional contractility and number of capillaries and arterial vessels were evaluated after three months. FGF-2, FGF-2+MCP-1, and vector, but not MCP-1 alone improved regional contractility at rest, whereas only FGF-2 alone ameliorated function under stress conditions. Angiogenesis in the ischemic area was stimulated by FGF-2 compared to MCP-1. In contrast, MCP-1 induced arteriogenesis relative to FGF-2. Differences for vessel growth and regional function were apparent between FGF-2 and MCP-1. This contrast could allow the speculation that development of a flow reserv...Continue Reading

References

Feb 23, 1995·Molecular and Cellular Biochemistry·R R PaduaE Kardami
Jan 1, 1997·Endothelium : Journal of Endothelial Cell Research·O ZachH Bauer
Jun 17, 1998·The Journal of Clinical Investigation·T MuroharaJ M Isner
Feb 13, 2001·Cardiovascular Research·I E HoeferW Schaper
Dec 7, 2002·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Claudia HeilmannGeorg Lutter
Dec 31, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Michiel VoskuilIvo R Buschmann
Apr 15, 2003·Trends in Cardiovascular Medicine·Rohit Khurana, Michael Simons
Jun 5, 2003·Nature Medicine·Peter Carmeliet
Oct 30, 2003·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Claudia A U HeilmannGeorg Lutter
Feb 14, 2004·Cardiovascular Research·Rainer SchulzGerd Heusch

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.